Crossmark

Comment on “When should Lenvatinib be switched to an alternative medication in patients with HCC who do not exhibit reactive blood pressure elevation?”

Crossref DOI link: https://doi.org/10.1038/s41440-025-02234-8

Published Online: 2025-05-21

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Akasaki, Yuichi

Shibata, Keisuke

Ohishi, Mitsuru
License Information

Text and Data Mining valid from 2025-05-21

Version of Record valid from 2025-05-21
More Information

Article History

Received: 1 April 2025

Revised: 11 April 2025

Accepted: 18 April 2025

First Online: 21 May 2025

Compliance with ethical standards

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below